Skip to main content
. 2021 Mar 16;325(11):1061–1073. doi: 10.1001/jama.2021.1489

Figure 2. Cumulative Incidence of Atrial Fibrillation According to Randomized Treatment Groups.

Figure 2.

A, Cumulative incidence of the primary end point according to randomized treatment group of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) vs placebo derived from Cox regression models controlling for age, sex, and vitamin D3 randomization group. Median observation time was 5.3 (interquartile range, 5.0-5.7) person-years. B, Cumulative incidence of the primary end point according to randomized treatment group of vitamin D3 vs placebo derived from Cox regression models controlling for age, sex, and EPA-DHA randomization group. Median observation time was 5.3 (interquartile range, 5.0-5.7) person-years.